The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies
Study Type
OBSERVATIONAL
Enrollment
1,000
N.N. Petrov NMRC of Oncology, Oncoimmunology dep.
Saint Petersburg, Russia
RECRUITINGProgression in 3 mo
Presence of disease progression within 3 mo from sample aquisition
Time frame: 3 month
Overall survival (OS)
Time from sample aquisition to death from any reason
Time frame: Up to 5 years
Progression free survival
Time from sample aquisition to progression or death from the disease
Time frame: Up to 5 years
Response rate
Response assesmenr with RECIST 1.1 and iRECIST
Time frame: During the intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.